Evidence map›Paper›PMID 30132202›Full record

ArticleInflammation2019

Oridonin Ameliorates Lipopolysaccharide-Induced Endometritis in Mice via Inhibition of the TLR-4/NF-κBpathway.

Min Zhou, Yinyi Yi, Li Hong

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. The role of toll-like receptors (TLRs) and their therapeutic applications in endometrial cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  9. Article
  10. Polysaccharide derived fromAmerican journal of translational research · 2022
    Article
  11. Article
  12. Ginsenoside Rb1 MitigatesMolecules (Basel, Switzerland) · 2021
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Min ZhouDepartment of Gynecology and Obstetrics, Renmin Hospital of Wuhan University, No.238 Jiefang Road, Wuchang District, Wuhan City, Hubei Province, People's Republic of China.
Yinyi YiDepartment of Gynecology and Obstetrics, Renmin Hospital of Wuhan University, No.238 Jiefang Road, Wuchang District, Wuhan City, Hubei Province, People's Republic of China.
Li HongDepartment of Gynecology and Obstetrics, Renmin Hospital of Wuhan University, No.238 Jiefang Road, Wuchang District, Wuhan City, Hubei Province, People's Republic of China. drhongli7777@gmail.com.
Renmin Hospital of Wuhan University · CNWuhan University · CN

Funding

National Natural Science Foundation of China 81471442
6 · The paper itself

Abstract

Endometritis is a health threat to both humans and animals and poses a huge economic burden. Oridonin (Ori) is a natural diterpenoid isolated from the traditional Chinese herb Rabdosiarubescens (R. rubescens) and has multiple health-promoting effects, including antioxidant, anti-inflammatory, and antitumor effects. There is little evidence showing that Ori can effectively treat endometritis, and the relevant mechanisms need to be further clarified. In this study, we investigated the effects of Ori on LPS-induced endometritis in vivo. Additionally, we examined the effects of Ori on LPS-stimulated mouse endometrial epithelial cells (mEECs). The results showed that Ori treatment significantly alleviated LPS-induced endometritis and reduced the activity of myeloperoxidase. ELISA and qPCR results indicated that Ori dose-dependently decreased the expression of TNF-α, IL-1β, and IL-6 both in tissues and in mEECs. In addition, Ori was found to inhibit LPS-induced TLR4/NF-κB signaling pathway activation. These results suggest that Ori effectively attenuates LPS-induced endometritis by inhibiting the TLR4/NF-κB signaling pathway and that Ori might be an effective drug for the prevention and treatment of LPS-induced endometritis.

Indexed as

AnimalsDiterpenes, KauraneEndometritisEpithelial CellsFemaleInterleukin-1betaInterleukin-6LipopolysaccharidesMiceNF-kappa BSignal TransductionToll-Like Receptor 4Tumor Necrosis Factor-alphaDiterpenes, KauraneInterleukin-1betaInterleukin-6LipopolysaccharidesNF-kappa BoridoninToll-Like Receptor 4Tumor Necrosis Factor-alphaendometritisinflammatory cytokinesNF-κBoridonin

Identifiers

PMID30132202
OpenAlexW2888169816

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.